Stealth BioTherapeutics to Report First Quarter Financial Results on Tuesday, May 18, 2021
Stealth BioTherapeutics Corp (NASDAQ: MITO) will release its first quarter 2021 financial results on May 18, 2021, before market opening. The company focuses on developing therapies for mitochondrial dysfunction and will hold a conference call at 8:30 AM ET on the same day to discuss the results and provide a business update. Investors can access the call via phone or through a live audio webcast on their investor website.
- Company focused on developing therapies for mitochondrial dysfunction.
- Lead product candidate, elamipretide, shows potential for treating rare diseases.
- None.
BOSTON, May 11, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it will report first quarter 2021 financial results on Tuesday, May 18, 2021, before the market opens.
Management will host a conference call at 8:30 am ET that day to discuss the financial results and provide a general business update. The call can be accessed by dialing (877)-407-0989 (domestic) or (201)-389-0921 (international) and referencing conference ID 13719019. A live audio webcast of the event can be accessed by visiting the Investors & News section of Stealth's Investor website, https://investor.stealthbt.com/. A replay of the webcast will be archived on Stealth's website for 30 days following the event.
About Stealth
We are a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in nearly every cell in the body, are the body's main source of energy production and are critical for normal organ function. Dysfunctional mitochondria characterize a number of rare genetic diseases and are involved in many common age-related diseases, typically involving organ systems with high energy demands such as the heart, the eye, and the brain. We believe our lead product candidate, elamipretide, has the potential to treat both rare metabolic cardiomyopathies, such as Barth, Duchenne muscular dystrophy and Friedreich's ataxia, rare mitochondrial diseases entailing nuclear DNA mutations, as well as ophthalmic diseases entailing mitochondrial dysfunction, such as dry age-related macular degeneration and Leber's hereditary optic neuropathy. We are evaluating our second-generation clinical-stage candidate, SBT-272, and our new series of small molecules, SBT-550, for rare neurological disease indications following promising preclinical data. We have optimized our discovery platform to identify novel mitochondria-targeted compounds which may be nominated as therapeutic product candidates or utilized as mitochondria-targeted vectors to deliver other compounds to mitochondria.
Investor Relations
Stern Investor Relations
Janhavi Mohite, 212-362-1200
IR@StealthBT.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/stealth-biotherapeutics-to-report-first-quarter-financial-results-on-tuesday-may-18-2021-301289064.html
SOURCE Stealth BioTherapeutics Inc.
FAQ
When will Stealth BioTherapeutics report its first quarter financial results?
What time will the earnings conference call be held for MITO?
How can I access the Stealth BioTherapeutics earnings call?
What is the focus of Stealth BioTherapeutics?
